

Brendon L Neuen Mbbs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2048762/publications.pdf>

Version: 2024-02-01

53
papers

3,072
citations

279778

23
h-index

182417

51
g-index

54
all docs

54
docs citations

54
times ranked

3008
citing authors

#	ARTICLE	IF	CITATIONS
1	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 845-854.	11.4	595
2	Chronic kidney disease. <i>Lancet</i> , 2021, 398, 786-802.	13.7	478
3	Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. <i>Circulation</i> , 2018, 138, 1537-1550.	1.6	200
4	Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1237-1250.	4.4	190
5	Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e014908.	3.7	161
6	Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. <i>BMJ: British Medical Journal</i> , 2019, 367, l5873.	2.3	131
7	Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2019, 171, 181.	3.9	108
8	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. <i>Circulation</i> , 2022, 145, 1460-1470.	1.6	97
9	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2229-2242.	6.1	93
10	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2925-2936.	6.1	82
11	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021, 42, 4891-4901.	2.2	80
12	Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 903-914.	11.4	73
13	Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. <i>Kidney International</i> , 2020, 98, 769-777.	5.2	69
14	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. <i>Circulation</i> , 2021, 143, 1735-1749.	1.6	60
15	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. <i>Stroke</i> , 2021, 52, 1545-1556.	2.0	60
16	Predictors of Patency after Balloon Angioplasty in Hemodialysis Fistulas: A Systematic Review. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 917-924.	0.5	52
17	Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. <i>Diabetologia</i> , 2021, 64, 2147-2158.	6.3	45
18	Sodium-Glucose cotransporter 2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 382-390.	4.4	40

#	ARTICLE	IF	CITATIONS
19	Neutrophil-lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients. <i>Renal Failure</i> , 2016, 38, 70-76.	2.1	39
20	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. <i>American Journal of Kidney Diseases</i> , 2021, 77, 23-34.e1.	1.9	38
21	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 384-395.	4.5	37
22	The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1753-1766.	4.4	31
23	Factors Associated with Patency Following Angioplasty of Hemodialysis Fistulae. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1419-1426.	0.5	29
24	Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey. <i>BMJ Open</i> , 2021, 11, e047245.	1.9	25
25	Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression. <i>American Journal of Kidney Diseases</i> , 2021, 78, 350-360.e1.	1.9	21
26	Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1072-1083.	4.4	20
27	Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 251-259.	4.5	19
28	Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, i48-i55.	0.7	18
29	A longitudinal faculty development program: supporting a culture of teaching. <i>BMC Medical Education</i> , 2019, 19, 400.	2.4	17
30	Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. <i>Cmaj</i> , 2019, 191, E1128-E1135.	2.0	17
31	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. <i>ESC Heart Failure</i> , 2021, 8, 1482-1493.	3.1	16
32	Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e021661.	3.7	16
33	Sodium-glucose cotransporter 2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 252-257.	4.4	12
34	Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities. <i>CardioRenal Medicine</i> , 2022, 12, 1-10.	1.9	12
35	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 291-303.	6.1	10
36	Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1927-1938.	4.4	10

#	ARTICLE	IF	CITATIONS
37	Availability, coverage, and scope of health information systems for kidney care across world countries and regions. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 159-167.	0.7	9
38	SGLT2 inhibitors and finerenone: one or the other or both?. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1209-1211.	0.7	9
39	Global kidney disease. <i>Lancet, The</i> , 2013, 382, 1243.	13.7	6
40	Lupus nephritis in Indigenous Australians: a single-centre study. <i>Internal Medicine Journal</i> , 2020, 50, 830-837.	0.8	6
41	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. <i>International Journal of Cardiology</i> , 2021, 324, 165-172.	1.7	6
42	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1652-1659.	4.4	6
43	Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. <i>Diabetologia</i> , 2021, 64, 2402-2414.	6.3	6
44	Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People With and Without Diabetes. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 298-308.	1.4	6
45	Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in Far North Queensland Australian adults. <i>Nephrology</i> , 2017, 22, 520-530.	1.6	3
46	Risk Factors for Incident Kidney Disease in Older Adults: an Australian Prospective Population-Based Study. <i>Internal Medicine Journal</i> , 2020, , .	0.8	3
47	Diagnostic Test Studies in Nephrology: Quantity, Quality, and Scope. <i>American Journal of Kidney Diseases</i> , 2011, 58, 921-927.	1.9	2
48	Endovascular Stent Placement for Hemodialysis Arteriovenous Access Stenosis. <i>International Journal of Vascular Medicine</i> , 2015, 2015, 1-7.	1.0	2
49	Regarding "Prospective, randomized study of cutting balloon angioplasty versus conventional balloon angioplasty for the treatment of hemodialysis access stenoses". <i>Journal of Vascular Surgery</i> , 2014, 60, 1122.	1.1	1
50	Pilot Trials in Nephrology: Establishing a BASE for Large-Scale Randomized Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 4-6.	6.1	1
51	Balloon inflation time in angioplasty of dialysis access stenosis. <i>Hemodialysis International</i> , 2014, 18, 847-848.	0.9	0
52	Reducing cardiovascular risk in people with diabetes and kidney disease. <i>Medical Journal of Australia</i> , 2018, 209, 438-439.	1.7	0
53	Endothelin Receptor Antagonists and Risk of Heart Failure in CKD. <i>JACC: Heart Failure</i> , 2022, 10, 508-511.	4.1	0